Wall Street closes at a record for the first time since end of January
PharmaCyte Biotech, Inc. (OTC:PMCB) CEO and President Joshua Silverman has recently purchased shares of the company’s common stock, according to a Form 4 filing with the Securities and Exchange Commission. Over three days, Silverman acquired a total of 100,000 shares for approximately $80,476, with prices ranging from $0.7831 to $0.8329 per share.
The transactions occurred between January 5 and January 7, 2026. On January 5, Silverman bought 30,000 shares at $0.7831 each. This was followed by another purchase of 30,000 shares on January 6, at a price of $0.7889 per share. The final transaction on January 7 involved the acquisition of 40,000 shares at $0.8329 each.
Following these transactions, Silverman directly owns 416,250 shares of PharmaCyte Biotech, Inc. In addition, Silverman indirectly owns 50,000 shares through JNS Holdings Group LLC.
In other recent news, PharmaCyte Biotech Inc has successfully monetized its stake in Femasys Inc, which has significantly bolstered its financial standing. The transaction is set to increase PharmaCyte’s cash and marketable securities to around $20 million, up from $13.3 million as of the end of July 2025. This development highlights PharmaCyte’s strategic approach to capital deployment, emphasizing a conservative risk profile. The company views this successful exit as a validation of its strategy. The move is part of recent developments that continue to shape the company’s financial landscape. Investors may find this increase in cash reserves noteworthy as it reflects PharmaCyte’s ongoing efforts to strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.